Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Guided User-initiated Insulin Dose Enhancements (GUIDE) to Improve Outcomes for Youth With Type 1 Diabetes

19. April 2022 aktualisiert von: Yale University
We propose conducting a pilot randomized study to assess the feasibility of using the automated insulin dose adjustment (AIDA) system to assist the parents of children with Type 1 Diabetes to make insulin dose adjustments between visits with their diabetes provider. Study results will be used to inform a larger RCT with an anticipated primary outcome of change in HbA1c in patients managed with either standard care (changes in therapy settings effected at regularly scheduled patients visits) or AIDA guided care.

Studienübersicht

Status

Zurückgezogen

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

Screening & End of 3-Week Run-in Period (Visit 1, Week 0) : Screening will be conducted by invitation to potentially eligible subjects. The study will be explained and written informed consent will be obtained from parents or patients (when 18 years of age or older) prior to conducting any study-related procedures. After written informed consent and patient assent (when <18 years of age) have been obtained, potential participants will undergo a history and physical exam. Girls of childbearing potential will have a urine pregnancy test performed at the time of the enrollment visit and the need for contraception for the entire duration of the study will be discussed. At this and all other study visits, participants/parents will meet with a diabetes care provider (i.e., a physician, nurse practitioner, or physician assistant) who will carry out a comprehensive review of diabetes management and review blood glucose and ketone records. The treatment regimen will be adjusted as clinically indicated during the initial screening visit and baseline data (including CGM and insulin dose data) will be collected in all participants during the 3-week run-in period of the study; HbA1c levels will be measured at the end of the 3-week baseline period in all eligible participants.

Baseline data obtained at the screening or 3-week baseline visit will include:

  • Demographic characteristics, including family income, highest parental education attained, and number of individuals in the home
  • 3-week data regarding CGM, insulin dose and Fitbit data
  • Anthropometric measures (height, weight, BMI, vital signs) and physical exam
  • Current diabetes care practices (frequency of self-monitored blood glucose (SMBG), insulin dosing, review of blood glucose values)
  • Medical History: duration of diabetes, comorbidities, past medical history, social history, family history, medications, and allergies
  • Additional diabetes history including current/past use of CGM, insulin pump, and other modes of diabetes technology
  • Frequency of Emergency Department visits due to decompensated diabetes (i.e., hyperglycemia, ketosis and DKA) over the past 6 months
  • Baseline laboratory assessment including lipid panel and urine microalbumin

  • Psychosocial Questionnaires will be administered

    1. Hypoglycemia Fear Survey (parent and child)
    2. Pittsburgh Sleep Quality Index
    3. Diabetes Treatment Satisfaction Questionnaire (DTSQ, DTSQc), which includes eight items, six of which form a scale (scored 0-36) in which higher scores indicate greater treatment satisfaction
    4. Diabetes-specific emotional distress using Problem Areas in Diabetes scale

After collection of all baseline data, eligible participants will be randomized to either the control or intervention group and receive instructions for the study. Participants will also be provided with a FitBit and instructed to wear this for the duration of the study to track activity levels. Participants in the intervention group will be required to upload their diabetes devices to Tidepool each week for the duration of the study. Tidepool is program used at Yale Pediatric Diabetes clinics as the current standard of care for uploading devices (pumps, CGMs, Bluetooth enabled pens) in our clinics and is HIPAA compliant. Participants may contact the Yale Diabetes Team for insulin dose adjustments or the study team at any point during the study if they have a question about the study.

Visit 2 (Week 13) & Visit 3 (Week 26): At these visits, all participants will meet with a diabetes care provider who will carry out a comprehensive review of diabetes management and review blood glucose and insulin records. Diabetes devices will be downloaded, and glycemic trends and insulin dosing regimens will be reviewed. The treatment regimen will be adjusted as clinically indicated.

After 26 weeks in the study, intervention group parents will be asked to participate in focus groups to discuss the study. These meetings will take place at the Yale Pediatric Diabetes Research Center.

Studientyp

Interventionell

Phase

  • Unzutreffend

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

7 Jahre bis 21 Jahre (Kind, Erwachsene)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

i. Clinical diagnosis of type 1 diabetes for at least 1 year ii. Ages 7-21 years iii. Participants 18 years of age must be able to read and provide written consent iv. Participants under 18 years of age must be able to read and provide written assent v. Participants are managed using an insulin pump or multiple daily injections vi. Participant has a CGM or is willing to wear a CGM for the duration of the study

Exclusion Criteria:

I. Hemoglobin A1c <7.5% or > 10.0% ii. Recent history of more than 1 episode of diabetic ketoacidosis (DKA) in the past 4 months iii. Treatment with glucose lowering drugs other than insulin iv. Females who are pregnant, lactating, or planning to become pregnant in the next 6 months v. Another medical condition that precludes participation in the study.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Aktiver Komparator: Automated Insulin Dose Adjustment (AIDA)
Using the AIDA system to assist the parents of children with T1D make insulin dose adjustments
Gerät: Automated Insulin Dose Adjustment
The system originally developed at Boston Children's Hospital, obtains CGM, insulin delivery, and activity data, from the cloud each day at approximately 8:00 PM using an Application Program Interface (API) calls to commercial companies (primarily Glooko and Tidepool) that aggregate data from different devices used to manage glucose levels in individuals. A detailed statistical and control analysis (see preliminary data study 1 for algorithm details) of the data are then conducted to determine if a change in therapy is required. If the analysis indicates a change in therapy is required, the patient or parent is notified by text or email directing then to a web portal detailing the change. The patient or parent can accept or modify the recommended change. If a change is made, the AIDA system confirms that the change is correctly implemented into the patient's pump or Bluetooth enabled pen when the patient next uploads the device data to the cloud.
Aktiver Komparator: Control
Standard Care - change in therapy settings effected a regularly scheduled patients visits
Gerät: Control
Standard Care - change in therapy settings effected at regularly scheduled patient visits

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Percent of patients at target range from baseline to 13 week
Zeitfenster: 13 weeks
Based on continuous glucose monitoring. Target range is defined as 70- 180 mg/dL
13 weeks
Percent of patients at target range from baseline to 26 weeks
Zeitfenster: 26 weeks
Based on continuous glucose monitoring. Target range is defined as 70- 180 mg/dL
26 weeks

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change from baseline in HbA1c
Zeitfenster: 13 weeks
This outcome will determine if there was a change in HbA1c levels from baseline to 13 weeks based on continuous glucose monitoring
13 weeks
Nighttime hypoglycemic defined as the % of time spent <55 mg/dL
Zeitfenster: Baseline
Based on continuous glucose monitoring
Baseline
Nighttime hypoglycemic defined as the % of time spent <55 mg/dL
Zeitfenster: 13 week
Based on continuous glucose monitoring
13 week
Nighttime hypoglycemic defined as the % of time spent <55 mg/dL
Zeitfenster: 26 week
Based on continuous glucose monitoring
26 week
Nighttime hypoglycemic defined as the % of time spent under 70 mg/dL
Zeitfenster: Baseline
Frequency of nighttime hypoglycemic events
Baseline
Nighttime hypoglycemic defined as the % of time spent under 70 mg/dL
Zeitfenster: 13 week
Frequency of nighttime hypoglycemic events
13 week
Nighttime hypoglycemic defined as the % of time spent under 70 mg/dL
Zeitfenster: 26 week
Frequency of nighttime hypoglycemic events
26 week
Percent of the recommendations that are accepted or modified by the family
Zeitfenster: 26 week
Percent of the recommendations that are accepted or modified by the family
26 week
Hypoglycemia Fear Survey
Zeitfenster: 26 weeks
This will be administered to the child and parent. The survey consists of 23 questions. Questions are answered using a 5 point likert scale ranging from never, rarely, sometimes, often, and always. The administration time is 10 minutes. The higher scores entail greater worry.
26 weeks
Pittsburgh Sleep Quality Survey (PSQI)
Zeitfenster: 26 weeks
The survey consists of 10 questions. The Questions relate to usual sleep habits over the last month, including time it takes to fall asleep, usual bedtime, hours of sleep per night, as well as questions about the frequency of sleep issues (not during the past month, less than once per week, once or twice per week, or three or more times per week). Higher scores suggest poorer sleep quality. The administration time is 5 minutes.
26 weeks
Diabetes Treatment Satisfaction Questionnaire (DTSQ)
Zeitfenster: 26 weeks
This will be administered to the parent and teen. The survey consists of 12-24 questions that are based on a likert scale ranging from 0 to 6. Higher scores entail greater satisfaction. The administration time is 10 minutes.
26 weeks
Problem Areas in Diabetes Scale (PAID)
Zeitfenster: 26 weeks
This is a questionnaire with 20 questions scaled from 0 to 4 on a likert scale. Questions involve feelings and emotional distress related to diabetes. Higher scores entail a more serious problem related to diabetes. The Administration time is 5 minutes.
26 weeks

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Yale University

Mitarbeiter

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Ermittler

  • Hauptermittler: Laura Nally, MD, Yale University

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Voraussichtlich)

1. September 2022

Primärer Abschluss (Voraussichtlich)

1. April 2023

Studienabschluss (Voraussichtlich)

1. April 2023

Studienanmeldedaten

Zuerst eingereicht

5. Februar 2020

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

5. Februar 2020

Zuerst gepostet (Tatsächlich)

6. Februar 2020

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

27. April 2022

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

19. April 2022

Zuletzt verifiziert

1. April 2022

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Schlüsselwörter

Zusätzliche relevante MeSH-Bedingungen

Andere Studien-ID-Nummern

  • 2000027002
  • 2K12DK094714-06 (US NIH Stipendium/Vertrag)

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Klinische Studien zur Diabetes Typ 1

Suchen Sie nach ähnlichen Studien

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

CROs by country

CROs in Qatar

Bedingungen

Seltene Krankheiten

Drogeninterventionen

Nahrungsergänzungsmittel

Sponsor / Mitarbeiter

Standorte

Abonnieren